All In Biotech

Drug Trial Radar · NCT05277571

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

109

Actual

Start

Mar 7, 2022

Primary completion

Jul 17, 2025

Study completion Sep 19, 2025

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Mar 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • UCB1381Biological

    UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

  • PlaceboDrug

    Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidents of treatment-emergent adverse events (TEAEs) from Baseline through the End of Study (EOS) Visit (Week 12) in Part ATime frame: From Baseline up to Week 12 in Part A
  2. Incidents of treatment-emergent serious adverse events (TESAEs) from Baseline through the EOS Visit (Week 12) in Part ATime frame: From Baseline up to Week 12 in Part A
  3. Incidents of TEAEs from Baseline through the EOS Visit (Week 22) in Part BTime frame: From Baseline up to Week 22 in Part B
  4. Incidents of TESAEs from Baseline through the EOS Visit (Week 22) in Part BTime frame: From Baseline up to Week 22 in Part B
  5. ≥75% improvement vs Baseline (Yes/No) in Eczema Area and Severity Index score (EASI75) at Week 12 in Part BTime frame: From Baseline up to Week 12 in Part B

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Up0110 125

    Beverly Hills, California

  • Up0110 101

    Glendale, California

  • Up0110 116

    Los Angeles, California

  • Up0110 121

    Northridge, California

  • Up0110 126

    Tustin, California

  • Up0110 127

    Valencia, California

  • Up0110 108

    Clearwater, Florida

  • Up0110 109

    Miami Lakes, Florida

  • Up0110 106

    Ocala, Florida

  • Up0110 102

    St. Petersburg, Florida

  • Up0110 111

    College Park, Georgia

  • Up0110 114

    Minneapolis, Minnesota

  • Up0110 107

    New York, New York

  • Up0110 124

    Winston-Salem, North Carolina

  • Up0110 104

    Oklahoma City, Oklahoma

  • Up0110 119

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.